Skip to content
Oncology

Empowering
actionable molecular
discoveries with NGS

Our lab runs blood-based biomarker analyses to detect, track, and monitor relevant mutations in circulating tumor DNA (ctDNA) at low levels (0.03-0.05%) with high specificity.

Test with us

Less invasive. Less time.
More confidence.

Partner with our lab for sensitivity, service, and accuracy — without the exponential cost.

ico
HPV-SEQ

Quantify HPV 16/18 from blood

  • HPV 16

  • HPV 18

Learn more
ico
HNSCC-SEQ

HPV(-) HNSCC mutation detection

  • CDKN2A

  • EGFR

  • ERBB2

  • FGFR3

  • HRAS

  • KRAS

  • NOTCH1

  • PIK3CA

  • PTEN

  • TP53

Learn more
ico
AML-SEQ™

Detect prevalent mutations with confidence

  • IDH1

  • IDH2

  • NPM1

Learn more
ico
AML-MRD-SEQ

A panel of promise for AML-MRD

  • FLT3

  • IDH1

  • IDH2

  • NPM1

  • BCOR

  • BRAF

  • CEBPA

  • GATA2

  • JAK2

  • KIT

  • KRAS

  • NRAS

  • PRPF8

  • PTPN11

  • SETBP1

  • SF3B1

  • SRSF2

  • TP53

  • U2AF1

  • ZRSR2

Learn more
ico
RAS-RAF-SEQ

RAS-RAF & PIK3 pathway markers

  • BRAF

  • KRAS

  • NRAS

  • AKT1

  • PIK3CA

Learn more
ico
BC-SEQ

Breast Cancer mutation detection

  • AKT1

  • ERBB2

  • ESR1

  • KRAS

  • PIK3CA

  • TP53

Learn more

Plasma-Safe-SeqS technology platform general test specifications

Cell-free DNA analysis for solid tumors Hematological malignancies
Sample types
accepted
  • Whole blood
  • Frozen plasma
  • Whole blood
  • Purified DNA isolated from bone barrow or blood
Sample
requirements
  • 2x10 mL blood collection tubes required, additional tube may be recommended for certain studies
  • Sysmex Inostics' specimen collection and shipping kits include Streck blood collection tubes
  • Plasma or purified cfDNA from samples collected in Streck or EDTA tubes is acceptable
  • 2x10 mL blood collection tubes required, additional tube may be recommended for certain studies
  • Sysmex Inostics' specimen collection and shipping kits include Streck blood collection tubes
  • DNA purified from BMMCs or PBMCs from 5x106 cells recommended
Turnaround
time		 7 – 10 Business Days
Performance

Plasma-Safe-SeqS can detect between 5-7 mutant molecules (95% CI) irrespective of the amount of wildtype DNA present and/or the panel configuration (3.3 - 66ng DNA). For 33 ng DNA input, this corresponds to 0.05-0.07% mutant allele frequency (MAF).

SYSMEX x QIAGEN

We joined forces with QIAGEN, another world-class company, to accelerate global CDx access. Our collective expertise allows us to anticipate and understand your specific needs throughout the clinical trial process.

Learn more

Featured articles

Featured image for With liquid biopsy, sensitivity matters
Blog | Feb. 15, 2023

With liquid biopsy, sensitivity matters
Featured image for Exploring key mutations in colorectal cancer (CRC)
Blog | Jan. 19, 2023

Exploring key mutations in colorectal cancer (CRC)
Featured image for Importance of PI3K-AKT pathway-based biomarkers in breast cancer
Blog | Jan. 11, 2023

Importance of PI3K-AKT pathway-based biomarkers in breast cancer
Featured image for The Prevalence and Outcomes of ESR1 Mutations in Breast Cancer
Blog | Dec. 07, 2022

The Prevalence and Outcomes of ESR1 Mutations in Breast Cancer
Contact

We’d love to hear from you!

Hidden
Hidden
Hidden